J L Blum

Summary

Affiliation: US Oncology
Country: USA

Publications

  1. ncbi request reprint The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer
    J L Blum
    U S Oncology, Dallas, Texas 75246, USA
    Oncologist 6:56-64. 2001
  2. ncbi request reprint Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma
    Pierre Fumoleau
    Cancer 98:1325-6; author reply 1326-7. 2003
  3. ncbi request reprint Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer
    Joyce A O'Shaughnessy
    Baylor Charles A Sammons Cancer Center, Dallas, TX 75246, USA
    Clin Breast Cancer 7:42-50. 2006
  4. ncbi request reprint Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy
    Stephen E Jones
    US Oncology Research Inc, Houston, TX, USA
    J Clin Oncol 25:4765-71. 2007
  5. doi request reprint Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes
    Joanne L Blum
    Baylor Charles A Sammons Cancer Center, Dallas, Texas, USA
    Clin Breast Cancer 7:850-6. 2007
  6. pmc Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Joanne Kotsopoulos
    Breast Cancer Res 14:R42. 2012
  7. doi request reprint Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer
    Joanne L Blum
    Baylor Charles A Sammons Cancer Center, Texas Oncology, US Oncology, 3410 Worth Street, Suite 400, Dallas, TX 75246, USA
    Breast Cancer Res Treat 136:777-88. 2012
  8. pmc Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers
    Susan L Neuhausen
    Department of Epidemiology, University of California Irvine, 224 Irvine Hall, Irvine, CA 92697, USA
    Breast Cancer Res 11:R76. 2009
  9. doi request reprint Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials
    Joanne L Blum
    Baylor Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, TX, 75246, USA
    Breast Cancer Res Treat 125:431-9. 2011
  10. ncbi request reprint Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy
    Joanne L Blum
    US Oncology Research, Inc, Houston, TX, USA
    Clin Breast Cancer 7:465-70. 2007

Collaborators

Detail Information

Publications19

  1. ncbi request reprint The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer
    J L Blum
    U S Oncology, Dallas, Texas 75246, USA
    Oncologist 6:56-64. 2001
    ..Capecitabine is an important new treatment option for breast cancer patients, and ongoing clinical trials should further define its role in a range of settings...
  2. ncbi request reprint Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma
    Pierre Fumoleau
    Cancer 98:1325-6; author reply 1326-7. 2003
  3. ncbi request reprint Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer
    Joyce A O'Shaughnessy
    Baylor Charles A Sammons Cancer Center, Dallas, TX 75246, USA
    Clin Breast Cancer 7:42-50. 2006
    ..Several ongoing randomized adjuvant and neoadjuvant clinical trials are assessing the clinical utility of capecitabine/taxane combinations in early-stage and locally advanced breast cancer...
  4. ncbi request reprint Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy
    Stephen E Jones
    US Oncology Research Inc, Houston, TX, USA
    J Clin Oncol 25:4765-71. 2007
    ..Hormonal breast cancer treatment increases menopausal symptoms in women. This study investigated differences between the symptoms associated with either adjuvant tamoxifen or exemestane...
  5. doi request reprint Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes
    Joanne L Blum
    Baylor Charles A Sammons Cancer Center, Dallas, Texas, USA
    Clin Breast Cancer 7:850-6. 2007
    ..We examined albumin-bound paclitaxel (100 mg/m2 or 125 mg/m2 administered weekly) to determine the antitumor activity in patients with MBC whose disease progressed despite conventional taxane therapy...
  6. pmc Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Joanne Kotsopoulos
    Breast Cancer Res 14:R42. 2012
    ..We present an updated analysis of breastfeeding and risk of breast cancer using a large matched sample of BRCA mutation carriers...
  7. doi request reprint Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer
    Joanne L Blum
    Baylor Charles A Sammons Cancer Center, Texas Oncology, US Oncology, 3410 Worth Street, Suite 400, Dallas, TX 75246, USA
    Breast Cancer Res Treat 136:777-88. 2012
    ..Multivariate analyses identified greater ORR, PFS, and OS with capecitabine in patients with ER and/or PgR-positive versus ER/PgR-negative tumors. Safety was in-line with previous phase III trials in MBC...
  8. pmc Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers
    Susan L Neuhausen
    Department of Epidemiology, University of California Irvine, 224 Irvine Hall, Irvine, CA 92697, USA
    Breast Cancer Res 11:R76. 2009
    ..In this study, we investigate the association of variants in genes involved in IGF signaling and risk of breast cancer in women who carry deleterious BRCA1 and BRCA2 mutations...
  9. doi request reprint Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials
    Joanne L Blum
    Baylor Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, TX, 75246, USA
    Breast Cancer Res Treat 125:431-9. 2011
    ..Frequency of AEs and serious AEs was not related to age at treatment, although women ≥ 65 years were more likely to withdraw from treatment because of an AE than younger women...
  10. ncbi request reprint Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy
    Joanne L Blum
    US Oncology Research, Inc, Houston, TX, USA
    Clin Breast Cancer 7:465-70. 2007
    ....
  11. ncbi request reprint Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer
    Joanne L Blum
    US Oncology Research Inc, Houston, USA
    J Clin Oncol 24:4384-90. 2006
    ..This trial was designed to determine the efficacy and tolerability of weekly paclitaxel plus capecitabine as first-line treatment for metastatic breast cancer (MBC)...
  12. ncbi request reprint Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients
    J L Blum
    U S Oncology, 3535 Worth Street, Suite 600, Dallas, TX 75246, USA
    Cancer 92:1759-68. 2001
    ..Capecitabine is an oral, tumor-targeted fluoropyrimidine carbamate with high activity in metastatic breast carcinoma and in paclitaxel-pretreated metastatic breast carcinoma...
  13. ncbi request reprint A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients
    M A Villalona-Calero
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA
    Ann Oncol 12:605-14. 2001
    ..The study also sought to recommend doses for subsequent disease-specific studies, identify clinically significant pharmacokinetic interactions, and detect preliminary antitumor activity...
  14. ncbi request reprint Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer
    Joyce A O'Shaughnessy
    Texas Oncology, PA, USA
    Clin Breast Cancer 6:143-9. 2005
    ..This phase II study evaluated the efficacy, safety, and health outcomes of pemetrexed treatment in heavily pretreated patients with advanced breast cancer...
  15. ncbi request reprint Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer
    Stephen E Jones
    US Oncology Research, Inc, Texas Oncology, Dallas, TX 75246, USA
    J Clin Oncol 24:5381-7. 2006
    ..In 1997, we initiated a randomized adjuvant trial of TC compared with standard-dose AC with a primary end point of disease-free survival (DFS)...
  16. ncbi request reprint Family environments of women seeking BRCA1/BRCA2 genetic mutation testing: an exploratory analysis
    Lisa A Keenan
    Department of Neuropsychology, Transitional Learning Center, Galveston, Texas 77550, USA
    J Genet Couns 13:157-76. 2004
    ..When compared with normative data, a subset consisting of the Ashkenazi Jewish women showed a trend of less cohesion than normal families, but similar cohesion levels as distressed families...
  17. pmc Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study
    Noah D Kauff
    Clinical Genetics and Gynecology Services, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 192, New York, NY 10021, USA
    J Clin Oncol 26:1331-7. 2008
    ....
  18. pmc Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Antonis C Antoniou
    Cancer Research UK, Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK
    Am J Hum Genet 82:937-48. 2008
    ....
  19. doi request reprint Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers
    Tara M Friebel
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
    Clin Breast Cancer 7:875-82. 2007
    ..The availability of these risk-reduction strategies is an important consideration in the decision to undergo genetic testing...